235 related articles for article (PubMed ID: 15841634)
61. Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream.
Weisberg NK; Varghese M
Dermatol Surg; 2002 Jun; 28(6):518-23. PubMed ID: 12081683
[TBL] [Abstract][Full Text] [Related]
62. Successful treatment of multifocal pigmented basal cell carcinomas with the application of topical 5% imiquimod cream.
Plachouri KM; Balasis S; Mallioris AF; Koumoundourou D; Georgiou S
Dermatol Ther; 2018 Sep; 31(5):e12685. PubMed ID: 30133929
[TBL] [Abstract][Full Text] [Related]
63. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
Sriprakash K; Godbolt A
Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
[TBL] [Abstract][Full Text] [Related]
64. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.
Tillman DK; Carroll MT
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s7-14. PubMed ID: 18277457
[TBL] [Abstract][Full Text] [Related]
65. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study.
van der Geer S; Martens J; van Roij J; Brand E; Ostertag JU; Verhaegh ME; Neumann HA; Krekels GA
Br J Dermatol; 2012 Jul; 167(1):110-5. PubMed ID: 22385074
[TBL] [Abstract][Full Text] [Related]
66. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments.
Pellegrini C; Orlandi A; Costanza G; Di Stefani A; Piccioni A; Di Cesare A; Chiricozzi A; Ferlosio A; Peris K; Fargnoli MC
PLoS One; 2017; 12(8):e0183415. PubMed ID: 28829805
[TBL] [Abstract][Full Text] [Related]
67. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
Love WE; Bernhard JD; Bordeaux JS
Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
[TBL] [Abstract][Full Text] [Related]
68. Superficial basal cell carcinoma on face treated with 5% imiquimod cream.
Malhotra AK; Bansal A; Mridha AR; Khaitan BK; Verma KK
Indian J Dermatol Venereol Leprol; 2006; 72(5):373-5. PubMed ID: 17050935
[TBL] [Abstract][Full Text] [Related]
69. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma.
Peris K; Micantonio T; Fargnoli MC; Lozzi GP; Chimenti S
J Am Acad Dermatol; 2006 Aug; 55(2):324-7. PubMed ID: 16844522
[TBL] [Abstract][Full Text] [Related]
70. Multiple basal cell carcinomas in a young adult treated with imiquimod 5%: a case report and literature review.
Bergman A; Contard P; Spencer J
J Drugs Dermatol; 2005; 4(1):95-7. PubMed ID: 15696993
[TBL] [Abstract][Full Text] [Related]
71. To the editor: incompletely excised basal cell carcinoma treated with 5% imiquimod cream.
Rivera A; Markus J; Pielop JA; Orengo I
Dermatol Surg; 2005 Nov; 31(11 Pt 1):1481-2. PubMed ID: 16416627
[No Abstract] [Full Text] [Related]
72. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC.
McKay KM; Sambrano BL; Fox PS; Bassett RL; Chon S; Prieto VG
Br J Dermatol; 2013 Sep; 169(3):549-54. PubMed ID: 23627639
[TBL] [Abstract][Full Text] [Related]
73. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma.
Spencer JM
Dermatol Surg; 2006 Jan; 32(1):63-9. PubMed ID: 16393600
[TBL] [Abstract][Full Text] [Related]
74. Local reactions to imiquimod in the treatment of basal cell carcinoma.
Tandon Y; Brodell RT
Dermatol Online J; 2012 Sep; 18(9):1. PubMed ID: 23031368
[TBL] [Abstract][Full Text] [Related]
75. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
Quirk C; Gebauer K; De'Ambrosis B; Slade HB; Meng TC
Cutis; 2010 Jun; 85(6):318-24. PubMed ID: 20666194
[TBL] [Abstract][Full Text] [Related]
76. Resolution of tinea pedis with imiquimod cream 5% in a patient with nodular basal cell carcinoma.
Stashower ME
Cutis; 2006 Jul; 78(1):66-9. PubMed ID: 16903324
[TBL] [Abstract][Full Text] [Related]
77. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study.
Choontanom R; Thanos S; Busse H; Stupp T
Graefes Arch Clin Exp Ophthalmol; 2007 Aug; 245(8):1217-20. PubMed ID: 17345092
[TBL] [Abstract][Full Text] [Related]
78. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice.
Daudén E;
J Eur Acad Dermatol Venereol; 2011 Nov; 25(11):1304-10. PubMed ID: 21348896
[TBL] [Abstract][Full Text] [Related]
79. Imiquimod in dermatology: an overview.
Hanna E; Abadi R; Abbas O
Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373
[TBL] [Abstract][Full Text] [Related]
80. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.
Wu JK; Oh C; Strutton G; Siller G
Australas J Dermatol; 2006 Feb; 47(1):46-8. PubMed ID: 16405483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
